Form4insider filings, from the source

SEC Form 4 · accession 0001213900-26-067505

InMed Pharmaceuticals Inc. · INM

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners
Period of report
May 20, 2026
Accepted (ET)
Jun 10, 2026 · 9:14 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001728328

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common SharesF3,F1May 20, 2026P51,056$1.56A543,129IBy Vivo Opportunity Fund Holdings, L.P.
Common SharesF3,F2May 20, 2026P5,154$1.56A54,833IBy Vivo Opportunity Cayman Fund, L.P.
Common SharesF4,F1May 21, 2026P30,882$1.69A574,011IBy Vivo Opportunity Fund Holdings, L.P.
Common SharesF4,F2May 21, 2026P3,118$1.69A57,951IBy Vivo Opportunity Cayman Fund, L.P.
Common SharesF5,F1May 29, 2026P16,164$1.57A590,175IBy Vivo Opportunity Fund Holdings, L.P.
Common SharesF5,F2May 29, 2026P1,632$1.57A59,583IBy Vivo Opportunity Cayman Fund, L.P.
Common SharesF6,F1Jun 1, 2026P14,838$1.55A605,013IBy Vivo Opportunity Fund Holdings, L.P.
Common SharesF6,F2Jun 1, 2026P1,498$1.55A61,081IBy Vivo Opportunity Cayman Fund, L.P.
Common SharesF7,F1Jun 2, 2026P20,753$1.52A625,766IBy Vivo Opportunity Fund Holdings, L.P.
Common SharesF7,F2Jun 2, 2026P2,095$1.52A63,176IBy Vivo Opportunity Cayman Fund, L.P.
Common SharesF8,F1Jun 3, 2026P7,069$1.55A632,835IBy Vivo Opportunity Fund Holdings, L.P.
Common SharesF8,F2Jun 3, 2026P714$1.55A63,890IBy Vivo Opportunity Cayman Fund, L.P.
Common SharesF9,F1Jun 4, 2026P6,125$1.57A638,960IBy Vivo Opportunity Fund Holdings, L.P.
Common SharesF9,F2Jun 4, 2026P618$1.57A64,508IBy Vivo Opportunity Cayman Fund, L.P.
Common SharesF10,F1Jun 5, 2026P49,966$1.57A688,926IBy Vivo Opportunity Fund Holdings, L.P.
Common SharesF10,F2Jun 5, 2026P5,045$1.57A69,553IBy Vivo Opportunity Cayman Fund, L.P.
Common SharesF11,F1Jun 8, 2026P29,518$1.52A718,444IBy Vivo Opportunity Fund Holdings, L.P.
Common SharesF11,F2Jun 8, 2026P2,982$1.52A72,535IBy Vivo Opportunity Cayman Fund, L.P.

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses